Skip to main content

Table 2 Trial size, blood pressure difference (mean change in active arm minus mean change in control arm), stroke events and stroke relative risk reduction

From: Is blood pressure reduction a valid surrogate endpoint for stroke prevention? an analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (BioSurrogate) evaluation schema (BSES)

Trial

Year

No.

Subject

s In

Active

Arm

No. Of

Subjec

ts In

Contro

l Arm

Systolic

Blood

Pressure

Difference

Diastolic

Blood

Pressure

Difference

Stroke

events in

Active

Arm

Stroke

events in

Control

Arm

Stroke

Relative

Risk

Reduction

ANBP1 [26]

1980

1721

1706

NR

5.7

13

22

0.41

IPPPSH [27]

1985

3185

3172

3.8

0.2

45

46

0.03

MRC-mild [28]

1985

8700

8654

10.3

6.2

60

109

0.45

HEP [29]

1986

419

465

18.0

11.0

23

44

0.42

SHEP [30]

1991

2365

2371

12.4

4.3

106

163

0.35

STOP [31]

1991

812

815

22.5

10.5

29

53

0.45

MRC-elderly [32]

1992

2183

2213

14.3

7.2

101

134

0.24

PATS [33]

1995

2824

2841

5.9

3.0

159

217

0.26

Syst-Eur [34]

1997

2398

2297

9.4

5.5

49

80

0.41

PREVENT [35]

2000

417

408

6.8

3.9

5

5

0.02

PROGRESS [36]

2001

3051

3054

9.0

4.0

317

420

0.24

EUROPA [37]

2003

6110

6108

5.0

2.0

98

102

0.04

SCOPE [38]

2003

2477

2460

3.5

2.9

89

115

0.23

HYVET-pilot [39]

2003

431

426

23.9

11.1

12

18

0.34

PEACE [40]

2004

4158

4132

3.0

1.2

71

92

0.23

ACTION [41]

2004

3825

3840

4.7

3.1

82

108

0.24

TRANSCEND [42]

2008

2954

2972

3.4

2.0

112

136

0.17

HYVET-main [43]

2008

1933

1912

12.0

6.0

51

69

0.27

  1. NR = Not Reported